Nanobiotix S.A (PA:NANO) — Market Cap & Net Worth
Market Cap & Net Worth: Nanobiotix S.A (NANO)
Nanobiotix S.A (PA:NANO) has a market capitalization of $1.39 Billion (€1.19 Billion) as of June 17, 2026. Listed on the PA stock exchange, this France-based company holds position #7714 globally and #127 in its home market, demonstrating a 2.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanobiotix S.A's stock price €31.84 by its total outstanding shares 48387950 (48.39 Million). Review NANO current and long-term liabilities to assess the company's total debt and financial obligations.
Nanobiotix S.A Market Cap History: 2015 to 2026
Nanobiotix S.A's market capitalization history from 2015 to 2026. Data shows growth from $897.21 Million to $1.80 Billion (6.42% CAGR).
Nanobiotix S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanobiotix S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-14.74x
Nanobiotix S.A's market cap is -14.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $897.21 Million | $4.02 Million | -$17.00 Million | 223.45x | N/A |
| 2016 | $873.45 Million | $5.42 Million | -$21.88 Million | 161.11x | N/A |
| 2017 | $838.94 Million | $3.72 Million | -$26.14 Million | 225.40x | N/A |
| 2018 | $658.48 Million | $3.48 Million | -$30.34 Million | 189.27x | N/A |
| 2019 | $468.40 Million | $68.00K | -$50.91 Million | 6888.30x | N/A |
| 2020 | $780.67 Million | $50.00K | -$33.59 Million | 15613.49x | N/A |
| 2021 | $413.53 Million | $10.00K | -$47.00 Million | 41353.11x | N/A |
| 2022 | $204.79 Million | $4.78 Million | -$57.04 Million | 42.88x | N/A |
| 2023 | $375.63 Million | $30.06 Million | -$39.70 Million | 12.50x | N/A |
| 2024 | $171.07 Million | $-11.61 Million | -$68.13 Million | -14.74x | N/A |
Competitor Companies of NANO by Market Capitalization
Companies near Nanobiotix S.A in the global market cap rankings as of June 17, 2026.
Key companies related to Nanobiotix S.A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Nanobiotix S.A Historical Marketcap From 2015 to 2026
Between 2015 and today, Nanobiotix S.A's market cap moved from $897.21 Million to $ 1.80 Billion, with a yearly change of 6.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.80 Billion | +63.28% |
| 2025 | €1.10 Billion | +544.84% |
| 2024 | €171.07 Million | -54.46% |
| 2023 | €375.63 Million | +83.43% |
| 2022 | €204.79 Million | -50.48% |
| 2021 | €413.53 Million | -47.03% |
| 2020 | €780.67 Million | +66.67% |
| 2019 | €468.40 Million | -28.87% |
| 2018 | €658.48 Million | -21.51% |
| 2017 | €838.94 Million | -3.95% |
| 2016 | €873.45 Million | -2.65% |
| 2015 | €897.21 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Nanobiotix S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.39 Billion USD |
| MoneyControl | $1.39 Billion USD |
| MarketWatch | $1.39 Billion USD |
| marketcap.company | $1.39 Billion USD |
| Reuters | $1.39 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanobiotix S.A
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more